EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 37 / No 3 (Mars 2021) Med Sci (Paris), 37 3 (2021) 235-241 References
Open Access
Issue
Med Sci (Paris)
Volume 37, Number 3, Mars 2021
Page(s) 235 - 241
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2021009
Published online 19 March 2021
  1. Larrey D.. Foie, médicaments et agents chimiques. Gastroenterol Clin Biol 2009 ; 33 : 1136–1146. [PubMed] [Google Scholar]
  2. Chiew AL, Gluud C, Brok J, et al. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev 2018 Feb. CD003328. [Google Scholar]
  3. Bénichou C.. Criteria of drug-induced liver disorders. J Hepatol 1990 ; 11 : 272–276. [CrossRef] [PubMed] [Google Scholar]
  4. Zhang X, Ouyang J, Thung SN. Histopathologic manifestations of drug-induced hepatotoxicity. Clin Liver Dis 2013 ; 17 : 547–564. [Google Scholar]
  5. Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014 ; 109 : 950–966. [Google Scholar]
  6. Megarbane B, Deye N, Baud F. Foie toxique : mécanismes lésionnels et thérapeutiques pharmacologiques spécifiques. Réanimation 2007 ; 16 : 632–642. [Google Scholar]
  7. Russmann S, Kullak-Ublick G, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009 ; 16 : 3041–3053. [PubMed] [Google Scholar]
  8. Gunawan BK, Liu Z, Han D, et al. c-Jun N-Terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology 2006 ; 131 : 165–178. [PubMed] [Google Scholar]
  9. Leist M, Single B, Castoldi AF, et al. Intracellular adenosine triphosphate (atp) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 1997 ; 185 : 1481–1486. [PubMed] [Google Scholar]
  10. Uetrecht J.. Immunoallergic Drug-induced liver injury in humans. Semin Liver Dis 2009 ; 29 : 383–392. [Google Scholar]
  11. Touloukian J, Kaplowitz N. Halothane-induced hepatic disease. Semin Liver Dis 1981 ; 1 : 134–142. [Google Scholar]
  12. Gunawan BK, Kaplowitz N. mechanisms of drug-induced liver disease. Clin Liver Dis 2007 ; 11 : 459–475. [Google Scholar]
  13. Kaplowitz N.. Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis 2002 ; 22 : 137–144. [Google Scholar]
  14. Kaplowitz N.. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005 ; 4 : 489–499. [Google Scholar]
  15. Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of iceland. Gastroenterology 2013 ; 144 : 1419–25e3. [PubMed] [Google Scholar]
  16. Mosedale M, Watkins PB. Understanding idiosyncratic toxicity: lessons learned from drug-induced liver injury. J Med Chem 2020; 63 : 6436–61. [PubMed] [Google Scholar]
  17. Kleiner DE. The histopathological evaluation of drug-induced liver injury. Histopathology 2017 ; 70 : 81–93. [PubMed] [Google Scholar]
  18. Gunawan B, Kaplowitz N. Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab Rev 2004 ; 36 : 301–312. [PubMed] [Google Scholar]
  19. Jaeschke H, McGill MR, Ramachandran A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. Drug Metab Rev 2012 ; 44 : 88–106. [PubMed] [Google Scholar]
  20. Han D, Dara L, Win S, et al. Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria. Trends Pharmacol Sci 2013 ; 34 : 243–253. [Google Scholar]
  21. Séguin B, Uetrecht J. The danger hypothesis applied to idiosyncratic drug reactions. Curr Opin Allergy Clin Immunol 2003 ; 3 : 235–242. [Google Scholar]
  22. Kato R, Uetrecht J. Supernatant from hepatocyte cultures with drugs that cause idiosyncratic liver injury activates macrophage inflammasomes. Chem Res Toxicol 2017 ; 30 : 1327–1332. [PubMed] [Google Scholar]
  23. Oda S, Matsuo K, Nakajima A, et al. A novel cell-based assay for the evaluation of immune- and inflammatory-related gene expression as biomarkers for the risk assessment of drug-induced liver injury. Toxicol Lett 2016 ; 241 : 60–70. [PubMed] [Google Scholar]
  24. Kegel V, Pfeiffer E, Burkhardt B, et al. Subtoxic concentrations of hepatotoxic drugs lead to Kupffer cell activation in a human in vitro liver model: an approach to study DILI. Mediators Inflamm 2015 ; 2015 : 1–14. [Google Scholar]
  25. Ogese MO, Faulkner L, Jenkins RE, et al. Characterization of drug-specific signaling between primary human hepatocytes and immune cells. Toxicol Sci 2017 ; 158 : 76–89. [PubMed] [Google Scholar]
  26. Mak A, Kato R, Weston K, et al. Editor’s highlight: an impaired immune tolerance animal model distinguishes the potential of troglitazone/pioglitazone and tolcapone/entacapone to cause IDILI. Toxicol Sci 2018 ; 161 : 412–420. [PubMed] [Google Scholar]
  27. Kim SH, Naisbitt DJ. Update on advances in research on idiosyncratic drug-induced liver injury. Allergy Asthma Immunol Res 2016 ; 8 : 3. [PubMed] [Google Scholar]
  28. Spraggs CF, Budde LR, Briley LP, et al. HLA-DQA1 * 02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011 ; 29 : 667–673. [PubMed] [Google Scholar]
  29. Kullak-Ublick GA, Andrade RJ, Merz M, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 2017 ; 66 : 1154–1164. [Google Scholar]
  30. Illing PT, Vivian JP, Dudek NL, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012 ; 486 : 554–558. [PubMed] [Google Scholar]
  31. Schrey AK, Nickel-Seeber J, Drwal MN, et al. Computational prediction of immune cell cytotoxicity. Food Chem Toxicol 2017 ; 107 : 150–166. [PubMed] [Google Scholar]
  32. Ghattaoraya GS, Dundar Y, González-Galarza FF, et al. A web resource for mining HLA associations with adverse drug reactions: HLA-ADR. Database 2016; 2016 : baw069. [PubMed] [Google Scholar]
  33. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc 2014 ; 89 : 95–106. [PubMed] [Google Scholar]
  34. Whritenour J, Ko M, Zong Q, et al. Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response. J Immunotoxicol 2017 ; 14 : 31–38. [PubMed] [Google Scholar]
  35. Benesic A, Leitl A, Gerbes AL. Monocyte-derived hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver injury. Gut 2016 ; 65 : 1555–1563. [Google Scholar]
  36. Benesic A, Rotter I, Dragoi D, et al. Development and validation of a test to identify drugs that cause idiosyncratic drug-induced liver injury. Clin Gastroenterol Hepatol 2018 ; 16 : 1488–94e5. [PubMed] [Google Scholar]
  37. Lakehal F, Dansette PM, Becquemont L, et al. Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem Res Toxicol 2001 ; 14 : 694–701. [PubMed] [Google Scholar]
  38. Jaskiewicz K, Voigt H, Blakolmer K. Increased matrix proteins, collagen and transforming growth factor are early markers of hepatotoxicity in patients on long-term methotrexate therapy. J Toxicol Clin Toxicol 1996 ; 34 : 301–305. [Google Scholar]
  39. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002 ; 22 : 27–42. [Google Scholar]
  40. DeLeve LD, Kaplowitz N. Mechanisms of drug-induced liver disease. Gastroenterol Clin North Am 1995 ; 24 : 787–810. [PubMed] [Google Scholar]
  41. Schiodt FV, Lee WM, Bondesen S, et al. Influence of acute and chronic alcohol intake on the clinical course and outcome in acetaminophen overdose. Aliment Pharmacol Ther 2002 ; 16 : 707–715. [Google Scholar]
  42. Đakovic´-Švajcer K, Samojlik I, Raškovic´ A, et al. The activity of liver oxidative enzymes after single and multiple grapefruit juice ingestion. Exp Toxicol Pathol 1999; 51 : 304–8. [PubMed] [Google Scholar]
  43. Hilmer SN, Shenfield GM, Le Couteur DG. Clinical implications of changes in hepatic drug metabolism in older people. Ther Clin Risk Manag 2005 ; 1 : 151–156. [PubMed] [Google Scholar]
  44. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008 ; 64 : 1147–1161. [Google Scholar]
  45. Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 2013 ; 58 : 388–396. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.